Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis
Our case report suggests the feasibility of the combination therapy of pembrolizumab plus lenvatinib for patients with metastatic renal cell carcinoma who are undergoing hemodialysis.
Authors
- Satoshi Muraoka
- Shin‐ichi Murata (ORCID: https://orcid.org/0000-0001-9862-3051)
- Hiroki Kawabata
- Takahito Wakamiya (ORCID: https://orcid.org/0000-0001-9101-1749)
- Isao Hara (ORCID: https://orcid.org/0000-0003-4542-4045)
- Yasuo Kohjimoto (ORCID: https://orcid.org/0000-0001-6103-6320)
- Shimpei Yamashita (ORCID: https://orcid.org/0000-0001-7402-6164)
- Yuya Iwahashi (ORCID: https://orcid.org/0000-0002-4201-1985)
- Fumiyoshi Kojima (ORCID: https://orcid.org/0000-0002-9478-9692)
Institutions
- Wakayama Medical University (JP)
Publication Details
- Journal
- IJU Case Reports
- Published
- 2025-03-09
- DOI
- https://doi.org/10.1002/iju5.70011
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05